|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1351739686 |
| 003 |
OCoLC |
| 005 |
20231120010713.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
221126s2022 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d UKAHL
|d SFB
|d OCLCF
|d OCLCQ
|d CUS
|
| 019 |
|
|
|a 1351739190
|
| 020 |
|
|
|a 9780323991759
|q (electronic bk.)
|
| 020 |
|
|
|a 0323991750
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323991766
|
| 035 |
|
|
|a (OCoLC)1351739686
|z (OCoLC)1351739190
|
| 050 |
|
4 |
|a RC347
|
| 082 |
0 |
4 |
|a 616.8
|2 23
|
| 245 |
0 |
0 |
|a Microbiome in neurological disease /
|c Edited by Timothy R. Sampson.
|
| 250 |
|
|
|a First edition.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press, an imprint of Elsevier
|c 2022.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v volume 167
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- Microbiome in Neurological Disease -- Copyright -- Contents -- Contributors -- Introduction: Unraveling the complex contributions of indigenous microbes to neurological health and disease -- We are not alone -- References -- Chapter One: Intersections of the microbiome and early neurodevelopment -- 1. Microbiota regulation of brain and behavior -- 2. Prenatal and early postnatal microbiota -- 2.1. Maternal intestinal microbiota -- 2.2. The vaginal microbiota -- 3. Impact of microbiota on neurodevelopment: Considerations of the developmental origins of health and disease -- 3.1. Maternal microbiota during pregnancy influences fetal development -- 3.2. Early postnatal microbiota influences fetal development -- 4. Potential mechanisms of microbiota influences on neurodevelopment -- 5. Future directions -- References -- Chapter Two: Microbiome influences on neuro-immune interactions in neurodegenerative disease -- 1. Introduction -- 2. Microbiome influences on microglia -- 3. Microbiome influences on astrocytes -- 4. Microbiome influences on other immune cells -- 5. Gut microbiome studies in human populations -- 6. Gut microbiome studies in model organisms of aging or neurological disease -- 7. Blood brain barrier (BBB) -- 8. Vagus nerve -- 9. Mediators of gut/brain crosstalk -- 9.1. Short chain fatty acids -- 9.2. Aryl hydrocarbon receptor (AHR) and AHR ligands -- 9.3. Lipopolysaccharide -- 9.4. Secondary bile acids -- 9.5. Neurotransmitters -- 10. Therapeutic potential of probiotics and prebiotics to treat neurodegenerative disease -- 11. Future challenges/directions -- Acknowledgments -- Conflict of interests -- References -- Chapter Three: The many genomes of Parkinson�s disease -- 1. Holistic view -- 1.1. Human holobiont -- 1.2. Complexities of PD -- 2. Hologenome -- 2.1. Human genome -- 2.2. Mitochondrial genome -- 2.3. Microbiome.
|
| 505 |
8 |
|
|a 8.1. Sodium oligomannate -- 8.2. Dietary inulin -- 9. Microbial mediators associated with Alzheimer�s disease -- 9.1. Short-chain fatty acids (SCFAs) -- 9.2. Bile acids -- 9.3. Polysaccharides -- 9.4. Toxins -- 10. Potential use of probiotics for the treatment of AD -- 10.1. Probiotic interventions can improve memory in models of Alzheimer�s disease -- 10.2. Human trials of probiotics for Alzheimer�s disease -- References -- Chapter Six: The microbiota-gut-brain axis in Huntington�s disease -- 1. Microbiota-gut-brain axis -- 1.1. Gut microbiota development -- 1.2. Studying the gut microbiome -- 1.3. Bi-directional communication -- 1.4. Short-chain fatty acids and branched-chain fatty acids -- 2. Gut microbiota disruption -- 2.1. Targeting the gut microbiota -- 3. Huntington�s disease -- 3.1. HD history and prevalence -- 3.2. HD etiology -- 3.3. HD pathology -- 3.4. HD clinical presentation -- 3.5. HD mouse models -- 4. The gut microbiota in HD -- 5. Gut microbiota and HD motor symptoms -- 6. Gut microbiota and HD-induced weight loss -- 7. Gut microbiota and cognition in HD -- 8. Gut microbiota and immune function in HD -- 9. Microbiota-gut-brain axis in HD -- 9.1. Mucosal function -- 9.2. Enteric nervous system and vagal nerve communication -- 9.3. HPA axis -- 10. Gut microbiota and HD sexual dimorphism -- 11. Environment -- 12. Limitations -- 13. Conclusion -- References -- Chapter Seven: Role of the gut microbiome in multiple sclerosis: From etiology to therapeutics -- 1. Microbiome associations studies in MS -- 2. Mechanisms of gut dysbiosis -- 2.1. Leaky gut and systemic inflammation -- 2.2. Modulation of the immune response by the gut microbiota -- 2.2.1. Suppression of the immunoregulatory response -- 2.2.2. Induction of a pro-inflammatory Th1/Th17 response by gut bacteria -- 3. Influence of diet on the pathobiology of MS.
|
| 505 |
8 |
|
|a 4. Targeting gut bacteria to treat multiple sclerosis -- 4.1. Probiotic-based therapy to treat autoimmune diseases -- 4.2. Bacteria as drugs (BRUGS) -- 4.3. Prebiotics/diet-based therapy -- 5. Conclusions -- Acknowledgments -- Conflict of interest statement -- References -- Chapter Eight: Interactions between the gut microbiome and ketogenic diet in refractory epilepsy -- 1. Introduction to epilepsy -- 2. Increasing interest in the microbiome and epilepsy -- 3. Ketogenic diet and epilepsy -- 4. Ketogenic diet impact on epilepsy via gut microbiome -- 4.1. Ketogenic diet on the composition of the gut microbiota in epilepsy -- 4.2. Ketogenic diet on the function of the gut microbiome in epilepsy -- 4.3. Ketogenic diet on the gut microbiome in other diseases -- 5. Potential mechanisms for microbial interactions with the ketogenic diet -- 5.1. Microbial effects on host lipid biology -- 5.2. Microbiome responses to variations in dietary fat content and type -- 6. Conclusion -- References -- Chapter Nine: Traumatic spinal cord injury and the contributions of the post-injury microbiome -- 1. Introduction -- 2. Remodeling of the gut microbiome after SCI -- 3. Interactions between the gut microbiome and SCI-induced neurogenic bowel -- 4. SCI-triggered local and systemic immune responses -- 5. Contributions of the microbiome to SCI-associated inflammation in humans -- 6. Microbiome contributions to SCI-associated inflammation in experimental models -- 7. SCI microbiome association with gut permeability after injury -- 8. Microbiome manipulations with therapeutic potential for SCI recovery -- 8.1. Fecal microbiome transplants -- 8.2. Probiotic therapeutics -- 8.3. Selective antibiotic treatment -- 8.4. Beneficial microbiome-related metabolites -- 9. Looking broadly into the future at microbiome effects on SCI -- Acknowledgments -- References.
|
| 650 |
|
0 |
|a Nervous system
|x Diseases
|x Microbiology.
|
| 650 |
|
0 |
|a Gastrointestinal system
|x Microbiology.
|
| 650 |
|
7 |
|a Gastrointestinal system
|x Microbiology.
|2 fast
|0 (OCoLC)fst00938889
|
| 700 |
1 |
|
|a Sampson, Timothy R.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Microbiome in neurological disease.
|b First edition.
|d [Cambridge, MA] : Academic Press, an imprint of Elsevier, 2022
|z 0323991769
|w (OCoLC)1322051253
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 167.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00747742/167
|z Texto completo
|
